Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-market Evaluation of Incidence Rate of Anaphylaxis and Hypersensitivity Reactions Associated With LUMISIGHT Administration

NCT07572162 is registered in ClinicalTrials.gov with Lumicell, Inc. as lead sponsor.

NCT NCT07572162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07572162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-market Evaluation of Incidence Rate of Anaphylaxis and Hypersensitivity Reactions Associated With LUMISIGHT Administration
Lead sponsor
Lumicell, Inc.
Phase
Observational
Overall status
Recruiting
Start date
September 30, 2026
Completion date
December 31, 2030
Enrollment
1,500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypersensitivity reactions